Celebrity Inventors
Glam girl Heddy Lamar may have used her good looks to good effect on the silver screen, but she put her smarts to better use as an inventor. During World War II, she co-patented a frequency-switching system for torpedo guidance that was considered years ahead of its time.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8022210 | Soluble amide and ester pyrazinoylguanidine sodium channel blockers The present invention relates to pyrazinoylguanidine compounds represented by formula (I): where X, Y and R1-R4 are as defined herein. The compounds of the present invention are useful as sodium channel blockers. ... | 09/20/2011 |
| 8008494 | Soluble amide and ester pyrazinoylguanidine sodium channel blockers The present invention relates to pyrazinoylguanidine compounds represented by formula (I): where X, Y and R1-R4 are as defined herein. The compounds of the present invention are useful as sodium channel blockers. ... | 08/30/2011 |
| 7642354 | Polycyclic pyrazines as potassium ion channel modulators The present invention provides a genus of polycyclic pyrazines of formula (I): wherein A and B are independently substituted or unsubstituted 5- or 6- membered heterocycloalkyl, or substituted or unsubstituted 5- or 6- memb... | 01/05/2010 |
| 7547782 | Met kinase inhibitors The present invention is directed to compounds having the formula I or II: including salts thereof, and methods for using them for the treatment of cancer. ... | 06/16/2009 |
| 7524957 | Compounds effecting glucokinase The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R1, R2, R3, n and m are as described in the specification, in the preparation of a medicament for the treatment or preventio... | 04/28/2009 |
| 7442702 | Prostaglandin agonists This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatmen... | 10/28/2008 |
| 7442701 | Amino-heterocycles as VR-1 antagonists for treating pain The present invention provides a compound of formula (I): wherein V represents NR5, O, S, SO or S(O)2; W and X each independently represent CH or N; Y represents N, CH or C—Ar2, with the proviso that at least one, but no more than ... | 10/28/2008 |
| 7419980 | Fused-aryl and heteroaryl derivatives and methods of their use The present invention is directed to fused-aryl and heteroaryl derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms... | 09/02/2008 |
| 7410972 | Compounds The invention provides N-pyrazinyl-thienylsulphonamides of formula (I) for use in the treatment of chemokine mediated diseases. Particularly inflammatory diseases, such as asthma ... | 08/12/2008 |
| 7407976 | Thiazoles and oxazoles useful as modulators of ATP-Binding Cassette transporters The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to meth... | 08/05/2008 |
| 7407961 | Pyrazine derivatives and pharmaceutical use thereof A pyrazine derivative of the following formula (I): or a salt thereof. The pyrazine compound (I) and a salt thereof of the present invention are adenosine antagonists and are useful for the prevention and/or treatme... | 08/05/2008 |
| 7407972 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade The present invention provides compounds of Formula (I): wherein A, B, C, G, and W1 have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are useful to treat thro... | 08/05/2008 |
| 7402606 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss Heterocycle substituted ketoamide derivatives of Formula (I), wherein the substitutes A, D, A and R are defined as in claim in, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such heterocycle ... | 07/22/2008 |
| 7384957 | 3,4-dihydro-1H-isoquinolin-2-yl-derivatives The present invention relates to novel compounds of formula I wherein the variable groups are as defined in the claims or a pharmaceutically acceptable acid addition salt thereof. The compounds of the invention are NK2 antagonists. | 06/10/2008 |
| 7384946 | Mmuscarinic acetylcholine receptor antagonists Novel dimeric benzoazabicyclohepatane compounds, pharmaceutical compositions, processes for their preparation and use thereof in treating M3 muscarinic acetylcholine receptor mediated diseases are disclosed. ... | 06/10/2008 |
| 7381719 | Diaryl ethers as opioid receptor antagonist A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3′, E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer o... | 06/03/2008 |
| 7368451 | Capped pyrazinoylguanidine sodium channel blockers The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers. ... | 05/06/2008 |
| 7368450 | Sodium channel blockers The present invention relates to compounds represented by formula (I): in which at least one of R3 and R4 is a group represented by formula (A): where the st... | 05/06/2008 |
| 7365073 | 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 Disclosed are certain 3-(heteroaryl)alanine derivatives which bind VLA-4 and inhibit leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, a... | 04/29/2008 |
| 7351807 | Cyanine-sulfenates for dual phototherapy Dye-sulfenate derivatives and their bioconjugates for dual phototherapy of tumors and other lesions. The compounds comprise sulfenates having the formula, t,0080 where E is selected from the group consisting of somatostatin receptor binding molecules, heat se... | 04/01/2008 |
| 7342019 | 5, 6-diaryl-pyrazine-2-amide derivatives as CBantagonists The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, prodrugs, solvates and crystalline forms thereof, in which R1 and R2 independently represent: a C1-6alkyl group; an optionally substitu... | 03/11/2008 |
| 7326706 | Pyrazine modulators of cannabinoid receptors The present application describes compounds according to Formula I, wherein A, G1, G2 and R1 are described herein. Additionally, the present application describes pharmaceutical compositions comprising at least one compound according... | 02/05/2008 |
| 7323470 | Viral polymerase inhibitors An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein wherein A, B, R2, R3, M1, M2, M3, M4, Y1 ... | 01/29/2008 |
| 7319100 | Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands Compounds provided herein are novel substituted pyrazinones, pyridines and pyrimidines of Formula (I) and (II): Such compounds are particularly useful as CRF receptor ligands, and hence, in the treatment of vario... | 01/15/2008 |
| 7312222 | Heterocyclic piperidines as modulators of chemokine receptor activity The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases. ... | 12/25/2007 |
| 7309699 | 3-Quinuclidinyl amino-substituted biaryl derivatives Compounds of formula (I) wherein A is N or N+—O−; n is 0, 1, or 2; Y is O, S, —NH—, and —N-alkyl-; Ar1 is both 6-membered aromatic rings; Ar2 is 5- or 6-membe... | 12/18/2007 |
| 7288652 | Method for preparing oltipraz Provided is a method for preparing oltipraz. The method includes reacting methyl 2-methyl-3-(pyrazin-2-yl)-3oxopropionate with phosphorus pentasulfide in the presence of a mixed solvent of toluene and xylene, followed by recrystallization. ... | 10/30/2007 |
| 7285551 | Fused-ring compounds and use thereof as drugs The present invention provides a fused ring compound of the following formula [I] wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, and a therapeutic agent for he... | 10/23/2007 |
| 7285554 | Pyrazole derivative Drugs, in particular, pyrazole derivatives represented by the following general formula (I) which have a calcium release-activated calcium channel inhibitory effect and medicinal compositions, in particular, calcium release-activated calcium channel inhibitors conta... | 10/23/2007 |
| 7282501 | Modulators of peroxisome proliferator activated receptors (PPAR) The present invention is directed to a compound of formula I, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomer thereof, which are useful in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hyperte... | 10/16/2007 |
| 7282502 | CCR9 inhibitors and methods of use thereof The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compound... | 10/16/2007 |
| 7279472 | Compounds useful as reversible inhibitors of cysteine proteases Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds | 10/09/2007 |
| 7276602 | Isothiazole derivatives useful as anticancer agents The invention relates to compounds of the formula 1 or pharmaceutically acceptable salts, prodrugs, solvates or hydrates thereof, wherein wherein X, R1, and R2 are as defined herein. The inv... | 10/02/2007 |
| 7273868 | Pyrazine derivatives 1. A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, wherein X is ═CH— or ═N—, Y is —NH—, —NR4—, —S—, ... | 09/25/2007 |
| 7262196 | Tri(cyclo) substituted amide glucokinase activator compounds Compounds of Formula (I): or pharmaceutically acceptable salts or N-oxides thereof, are useful in the prophylactic and therapeutic treatment of hyperglycemia and diabetes. ... | 08/28/2007 |
| 7259175 | Peroxisome proliferator activated receptor modulators The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts thereof, Formula I: wherein: (a) R5 is selected from the group consisting of (C1-C6) alkyl, (C1-C | 08/21/2007 |
| 7256192 | Aromatic diamide derivatives, chemicals for agricultural or horticultural use and usage thereof The present invention relates to an aromatic diamide derivative represented by the general formula (I): [A1 is optionally substituted (C1-C8)alkylene grou... | 08/14/2007 |
| 7253188 | Aminobenzamide derivative This invention relates to a novel compound represented by the formula (I): or a pharmaceutically acceptable salt thereof, wherein R1 is —S(O)p-A, ... | 08/07/2007 |
| 7253197 | Aminothiazole derivatives Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R4 have the significance given in the specification, and the compounds, salts and esters... | 08/07/2007 |
| 7250418 | Compounds as CRFreceptor antagonists The present invention relates to compounds of Formula I, or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The compounds of the inventions are CRF1 receptor a... | 07/31/2007 |
